Luminex and One Lambda Renew Long-Term Strategic Partnership
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Luminex Corporation and One Lambda, Inc., have agreed to a long-term renewal of their 10-year strategic partnership aimed at developing platforms and technologies for human leukocyte antigen (HLA) typing and antibody screening for the organ transplantation market. Begun in 2000, their dedicated collaboration has resulted in the creation of innovative products that have made pre- and post-transplant diagnostics faster, and cost-efficient.
"One Lambda and Luminex combined the power of Luminex's xMAP® Technology with One Lambda's expertise in HLA testing and organ transplantation to dramatically advance the care available to those undergoing transplants," said George Ayoub, president and CEO of One Lambda. "Our platforms have significantly enhanced healthcare providers' ability to care for organ transplant patients by delivering vital information that helps them to better match donors with recipients."
Effective diagnostics are essential in transplant medicine. HLA typing and antibody screening are critical in matching organ donors and organ recipients, minimizing rejection and maintaining transplant patients' long-term health following a transplant. This kind of testing can require screening a patient for hundreds of HLA markers and antibodies. One Lambda's dedication to innovation ensures their products are continually updated with the latest donor registry data and new DNA genotypes. The simplicity and flexibility of the xMAP Technology platform to analyze both nucleic acids and proteins has allowed One Lambda to enhance and expand their product menu.
"Luminex and One Lambda have set the standard for strategic partnership with our collaboration that has delivered new technology and transformed the practice of transplantation medicine," said Patrick J. Balthrop, president and CEO of Luminex. "One Lambda has an impressive history of innovation in the field of transplantation, and we expect that our work together will continue to deliver significant technology advances and market leadership into the next decade."
One Lambda adopted Luminex's xMAP Technology to create products that could reduce the cost and complexity of HLA typing and antibody screening. The xMAP platform, which allows multiple, simultaneous tests to be run on a single sample, proved to be an ideal fit for transplant testing. The flexible technology helped One Lambda to develop a range of assays that have streamlined transplant diagnostics. One Lambda's LABType® SSO and LABScreen® products can detect up to 500 HLA specificities in a single test, eliminating the need to run multiple tests. One Lambda's xMAP-based assays are used in more than 80 countries worldwide.
"One Lambda and Luminex combined the power of Luminex's xMAP® Technology with One Lambda's expertise in HLA testing and organ transplantation to dramatically advance the care available to those undergoing transplants," said George Ayoub, president and CEO of One Lambda. "Our platforms have significantly enhanced healthcare providers' ability to care for organ transplant patients by delivering vital information that helps them to better match donors with recipients."
Effective diagnostics are essential in transplant medicine. HLA typing and antibody screening are critical in matching organ donors and organ recipients, minimizing rejection and maintaining transplant patients' long-term health following a transplant. This kind of testing can require screening a patient for hundreds of HLA markers and antibodies. One Lambda's dedication to innovation ensures their products are continually updated with the latest donor registry data and new DNA genotypes. The simplicity and flexibility of the xMAP Technology platform to analyze both nucleic acids and proteins has allowed One Lambda to enhance and expand their product menu.
"Luminex and One Lambda have set the standard for strategic partnership with our collaboration that has delivered new technology and transformed the practice of transplantation medicine," said Patrick J. Balthrop, president and CEO of Luminex. "One Lambda has an impressive history of innovation in the field of transplantation, and we expect that our work together will continue to deliver significant technology advances and market leadership into the next decade."
One Lambda adopted Luminex's xMAP Technology to create products that could reduce the cost and complexity of HLA typing and antibody screening. The xMAP platform, which allows multiple, simultaneous tests to be run on a single sample, proved to be an ideal fit for transplant testing. The flexible technology helped One Lambda to develop a range of assays that have streamlined transplant diagnostics. One Lambda's LABType® SSO and LABScreen® products can detect up to 500 HLA specificities in a single test, eliminating the need to run multiple tests. One Lambda's xMAP-based assays are used in more than 80 countries worldwide.
